How GLP1Ra affects lean body tissue as well as fat

Glucagon-like peptide 1 receptor agonists (GLP1Ra) may lead to reductions in lean tissue, including skeletal muscle and bone, while managing obesity and cardiometabolic disease.

• GLP1Ra are effective for weight loss in individuals with obesity and cardiometabolic disease.
• Treatment with GLP1Ra is associated with decreases in lean tissue mass.
• Skeletal muscle and bone may be particularly affected by GLP1Ra treatment.
• Strategies have been explored to reduce the loss of lean tissue during GLP1Ra therapy.
• Future research is needed to address the impacts of GLP1Ra on muscle and bone health.

Simplified